UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis
· FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment option with potential to fulfil the unmet medical needs for people affected by atopic dermatitis (AD) · AD is the most common chronic inflammatory skin disease in the developed world · Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of psoriasis and hidradenitis suppurativa (HS) Hellerup, Denmark, 4 November 2021 – UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, pharmaceutical company